Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales

Exact Sciences, Mayo Clinic share early data on esophageal cancer test

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

3 Growth Stocks to Buy at 52-Week Lows in March

How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%

How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?

Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the company

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)

Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM

Guardant posts data for colon cancer blood test amid push from rivals

Cathie Wood Darling Exact Sciences Rises On Highly Anticipated Colon Cancer News